Amgen Slumps 0.72 as 700M Volume Ranks 150th Amid Sector Pressures and Regulatory Timelines

On September 15, 2025, , , ranking 150th in terms of trading activity among listed stocks. The biotech giant's performance drew attention amid mixed market conditions and sector-specific dynamics.

Recent developments highlight strategic challenges for Amgen as it navigates competitive pressures in its core therapeutic areas. Analysts noted that the stock's underperformance relative to broader market indices reflects investor caution toward near-term earnings visibility, particularly in light of evolving regulatory timelines for key pipeline assets.

, though short-term volatility persists due to macroeconomic uncertainties. , suggesting a recalibration of risk appetite among major stakeholders.

To build an accurate back-test we need to formalise a few practical details that the original request leaves open. Below are the key items together with sensible defaults I can apply if you’d prefer not to fine-tune them. Universe of stocks: all common stocks listed on NYSE, . , . , with all capital redeployed daily. Costs & slippage: transaction fees and market impact are excluded by default. ; . Please let me know if these defaults are acceptable or if you’d like any changes.